Selank vs Orforglipron
Side-by-side comparison of key properties, dosing, and research.
Cognitive Enhancement
SelankGLP-1 / Weight Loss Agonists
Orforglipron- Summary
- Selank is a synthetic heptapeptide analog of tuftsin developed in Russia. It is a potent anxiolytic that reduces anxiety and enhances cognitive function without sedation or addiction. It is approved for clinical use in Russia for anxiety disorders.
- Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
- Half-Life
- Minutes (but effects persist for hours)
- ~12 hours (once-daily oral dosing)
- Admin Route
- SubQ, Intranasal
- Oral
- Research
- —
- —
- Typical Dose
- 250–500 mcg
- 12 mg → 24 mg → 36 mg → 45 mg
- Frequency
- 1–3 times daily
- Once daily
- Key Benefits
- Reduces anxiety without sedation
- Enhances memory and learning
- Improves focus and concentration
- Stabilizes mood
- Reduces physiological stress response
- May enhance motivation
- No addiction potential or withdrawal
- Fast-acting — effects within 20–30 minutes
- Approved clinically in Russia for anxiety disorders
- Oral pill — no injections required
- Once-daily dosing without food restrictions (unlike oral semaglutide)
- Up to 9.4% body weight reduction in Phase 2 at 36 weeks
- Significant HbA1c reduction in type 2 diabetes trials
- Small-molecule stability — no cold chain requirements
- Broadens access for injection-averse patients
- Potential class-defining convenience advantage over injectable GLP-1s
- Side Effects
- Mild sedation at higher doses (paradoxical)
- Fatigue (rare)
- Irritability during discontinuation (uncommon)
- Nausea (most common, dose-dependent)
- Vomiting
- Diarrhea
- Decreased appetite
- +2 more
- Stacks With
- —
- —